Eighty-one percent of surveyed women want noninvasive cervical cancer test over Pap test.
| Zdroj: | Biotech Week; 1/7/2004, p511-512, 2p |
|---|---|
| Abstrakt: | Presents the percentage of surveyed women who want SpectRx's noninvasive cervical cancer test over invasive Pap test in the U.S. Advantages of SpectRx test over Pap tests; Statement of Keith D. Ignotz, senior executive vice president of SpectRx Inc.; Reason for use of noninvasive cervical cancer test. |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|